DICKSON M A,SCHWARTZ G K.Development of cell-cycle inhibitors for cancer therapy[J].Curr Oncol,2009,16(2):36-43.
[2]
ALDOSS I T,TASHI T,GANTI A K.Seliciclib in malignancies[J].Expert Opin Inv Drug,2009,18(12):1957-1965.
[3]
MEIJER L.Chemical inhibitors of cyclin-dependent kinesis[J].Trends Cell Biol,1996,6(10):393-397.
[4]
MGBONYEBI O P,RUSSO J,RUSSO I H.Roscovitine induces cell death and morphologicalchanges indicative of apoptosis in MDA-MB-231 breast cancer cells[J].Cancer Res,1999,59(8):1903-1910.
[5]
ALVI A J,AUSTEN B,WESTON V J,et al.A novel CDK inhibitor,CYC202(R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival[J].Blood,2005,105(11):4484-4491.
[6]
APPLEYARD M V,O’NEILL M A,MURRAY K E,et al.Seliciclib(CYC202, R-roscovitine)enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model[J].Int J Cancer,2009,124(2):465-472.
[7]
LJUNGMAN M,PAULSEN M T.The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382[J].Mol Pharmacol,2001,60(4):785-789.
HUANG H,REGAN KM,LOU Z,et al.CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage[J].Science,2006,314(5797):294-297.
[15]
RAYNAUD F I,WHITTAKER S R,FISCHER P M,et al.In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine,bohemine and CYC202[J].Clin Cancer Res,2005,11(13):4875-4887.
